Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A very low-calorie, protein-based formula designed for enteral administration via a nasogastric tube, primarily investigated for the short-term (2-week) management of severe obesity. This specific formulation is composed of a fixed amount of various amino acids (arginine, ornithine-alpha-ketoglutarate, taurine, cysteine, tryptophan, hydroxyproline, citrulline), milk whey proteins, linseed oil, L-carnitine, coenzyme Q10, policosanols, fructooligosaccharides, and electrolytes (sodium, potassium, chloride). Its therapeutic effect is attributed to significant caloric restriction, the satiating effect of its high protein content, and the induction of ketogenesis, leading to substantial weight loss and improvement in cardiometabolic risk factors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Very Low-Calorie Enteral Protein-Based Formula.